195 related articles for article (PubMed ID: 12490695)
1. Voriconazole versus amphotericin B for invasive aspergillosis.
Blot F; Edé C; Nitenberg GM
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695
[No Abstract] [Full Text] [Related]
2. Voriconazole versus amphotericin B for invasive aspergillosis.
Karthaus M
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12494937
[No Abstract] [Full Text] [Related]
3. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
5. Successful management of invasive aspergillosis with voriconazole and amphoteracin B therapy in a patient with acute mycloid leukemia (AML-M2).
Manzoor NF; Azim S; Fadoo Z
J Pak Med Assoc; 2010 Nov; 60(11):977-9. PubMed ID: 21375212
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
7. Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies.
Herbrecht R
Ann Hematol; 2002; 81 Suppl 2():S52-3. PubMed ID: 12611078
[No Abstract] [Full Text] [Related]
8. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
Pagano L; Valentini CG; Fianchi L; Caira M
J Chemother; 2011 Feb; 23(1):5-8. PubMed ID: 21482486
[TBL] [Abstract][Full Text] [Related]
10. An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis.
Chow L; Brown NE; Kunimoto D
Clin Infect Dis; 2002 Nov; 35(9):e106-10. PubMed ID: 12384856
[TBL] [Abstract][Full Text] [Related]
11. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.
Frankenbusch K; Eifinger F; Kribs A; Rengelshauseu J; Roth B
J Perinatol; 2006 Aug; 26(8):511-4. PubMed ID: 16871222
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B is still the drug of choice for invasive aspergillosis.
Agarwal R; Singh N
Am J Respir Crit Care Med; 2006 Jul; 174(1):102; author reply 102-3. PubMed ID: 16793999
[No Abstract] [Full Text] [Related]
13. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
14. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
16. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation.
Wieland T; Liebold A; Jagiello M; Retzl G; Birnbaum DE
J Heart Lung Transplant; 2005 Jan; 24(1):102-4. PubMed ID: 15653389
[TBL] [Abstract][Full Text] [Related]
17. Combination antifungal therapy for invasive aspergillosis.
Cesaro S; Visintin G
Clin Infect Dis; 2005 Apr; 40(7):1073-5; author reply 1075-6. PubMed ID: 15825015
[No Abstract] [Full Text] [Related]
18. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Ullmann AJ; Heussel CP; Cornely OA
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
[No Abstract] [Full Text] [Related]
19. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Apisarnthanarak A; Little JR; Tebas P
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041527
[No Abstract] [Full Text] [Related]
20. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease.
van 't Hek LG; Verweij PE; Weemaes CM; van Dalen R; Yntema JB; Meis JF
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1694-6. PubMed ID: 9603157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]